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Abstract
Objective—To describe a study of medical monitoring methods and lessons learned in detecting 
health outcomes in U.S. plants producing toluene diisocyanate (TDI).
Methods—A multidisciplinary team implemented a medical and environmental monitoring 
program in three TDI plants.
Results—Of 269 eligible workers, 197 (73%) participated and 42 (21%) met symptom and/or 
lung function criteria that would trigger evaluation for possible asthma over five years of data 
collection. Subsequent evaluation was delayed for most, and a web-based data collection system 
improved timeliness.
Conclusions—Medical monitoring of TDI workers identified workers triggering further 
assessment per study protocol. Systems and/or personnel to ensure rapid follow-up are needed to 
highlight when triggering events represent potential cases of asthma needing further evaluation. 
Implementation of a research protocol requires resources and oversight beyond an occupational 
health program.
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Workplace exposures to diisocyanates may have adverse respiratory health effects including 
the potential for work-related occupational asthma. Occupational asthma (OA) is defined as 
asthma caused by exposure to an agent specific to a workplace.1 It is a subset of work-
related asthma (WRA) which includes pre-existing asthma made worse by workplace 
exposures (work-exacerbated asthma).1 Diisocyanates are known sensitizers and have long 
been recognized as capable of inducing asthma.2–7 Toluene diisocyanate (TDI) is a 
commonly used diisocyanate and a known cause of OA. This highly reactive monomer has a 
diversity of applications in flexible polyurethane foam, coatings, and elastomers. Workplace 
exposure to TDI may occur during the manufacturing process or in the production or 
application of TDI-containing polyurethane products.7 However, evidence from state-based 
and occupational health surveillance systems in other countries and workplace studies 
suggests that occurrences of OA due to diisocyanates in general and TDI in particular are 
declining, despite increases in the total number of workplaces using diisocyanates.8–12 This 
downward trend in diisocyanate-induced OA is probably related to reduced workplace 
exposures attributed to improved engineering controls, increased usage of respiratory 
protection, and/or effective medical surveillance.12
Medical monitoring programs implemented in workplaces producing or using diisocyanates 
may be successful at detecting isocyanate asthma, reducing the severity of asthma, and 
improving prognosis when workers are removed early from further exposures.12–14 For 
example, a medical monitoring program introduced in Ontario, Canada in 1983, likely 
contributed to a reduction in accepted compensation claims for OA, earlier detection of 
diisocyanate-induced OA, and a less severe health outcome among those diagnosed.15,16 
Companies with medical monitoring programs diagnose OA after symptom onset an average 
of one year earlier than companies without such programs.15
Medical surveillance programs for occupational asthma ideally involve a multidisciplinary 
team approach to surveillance comprising medical and nursing professionals, 
epidemiologists, and industrial hygienists. They have included a pre-placement baseline 
examination followed by a periodic (usually annual) health encounter of workers having 
potential relevant exposure, with more frequent health encounters during the first two years 
of exposure.13 Pre-placement exams and health encounters typically include questionnaire 
items regarding jobs, exposures, and work-related upper and lower respiratory symptoms;13 
lung function measurements, i.e. spirometry;17 and immunological tests as appropriate and 
feasible to detect a pre-disease state.13,16,17 However, the effectiveness of medical 
surveillance programs for occupational asthma warrants further evaluation.
This paper reports on lessons learned from the planning and conduct of a complex study to 
evaluate the effectiveness of a structured monitoring program designed to facilitate rapid 
standardized clinical evaluation of potential cases of asthma. Three companion papers report 
on exposure assessment, health outcomes and their relationship to TDI exposures, and lung 
function of the cohort over time.18–20
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Background
In 2003, the National Institute for Occupational Safety and Health (NIOSH), part of the 
Centers for Disease Control (CDC); member companies of the American Chemistry Council 
(ACC) Diisocyanates Panel; and the International Chemical Workers Union Council 
(ICWUC) established a collaborative research and development program to improve the 
management of health risks associated with occupational exposure to diisocyanates. The 
objectives of the program were to:
• characterize workplace TDI environmental concentrations based on use of 
standardized industrial hygiene monitoring and assessment procedures;
• monitor employee health through questionnaires and spirometry, using 
approaches that help ensure maximal participation;
• investigate potential cases of OA using a standardized medical evaluation process 
and evaluation of historical exposure experience;
• create a registry of OA cases, if any, occurring among workers with potential 
exposure to TDI in the production environment;
• evaluate the effectiveness of the program methods, including the standardized 
health and environmental monitoring procedures; and
• communicate the program findings to study participants, plant management, and 
the scientific community in a manner consistent with CDC and ACC guidelines 
for assuring the quality, objectivity, utility, and integrity of the information 
presented.
As part of the program, all U.S. TDI production plants planned to enroll all employees with 
potential TDI exposure into a structured medical and environmental monitoring program 
during 2006 through 2012. Contractors were not included. While all participating plants had 
on-going medical monitoring programs for TDI-exposed workers, this project aimed to 
standardize medical monitoring, clinical evaluation, and reporting across the TDI production 
plants in order to generate consistent data that could be analyzed in aggregate. This paper 
describes the standardized medical monitoring program, the cohort enrolled, outcomes, 
program successes and limitations, and approaches implemented to improve data collection 
and decision-making at the level of the plant occupational health facilities.
The medical surveillance program had three aims:
• define and test a practical, science-based model program for medical monitoring 
of employees working with diisocyanates and evaluate the operating 
characteristics (sensitivity and specificity) of various components of the program 
in identifying cases consistent with work-aggravated, work-related, and TDI-
induced asthma;
• assess the effectiveness of specific methods (e.g., questionnaire, spirometry) and 
protocol (e.g., frequency, timing) of medical monitoring programs, using 
monitoring and follow-up data obtained during clinical evaluation of TDI-
production employees; and
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• determine to what extent utilization of a standardized medical monitoring 
program facilitates early detection of TDI-induced asthma cases and leads to a 
favorable outcome after cessation of exposure.
METHODS
Study Design and Participants
Representatives of five companies comprising four TDI production plants and two plants 
using TDI participated in the initial project planning. One of the germinal concepts for this 
study was to layer data collection on top of each participating company’s medical 
surveillance and exposure assessment programs. Each participating company and each 
participating plant had its own medical surveillance program of its potentially exposed TDI 
workers. These programs pre-dated this project and continued following completion of the 
data collection phase of this project. While the company medical programs were similar, 
they were not identical. Much time and effort was expended prior to data collection in 
developing a detailed study protocol prior to enrolling participants and initiating data 
collection. This was done so that spirometry measurements and clinical classifications could 
be treated as equivalent between the different sources and could legitimately be pooled for 
analysis.
Before the study started, the two plants using TDI and one of the TDI producing plants 
ceased operation and became ineligible to participate prior to the start of data collection. 
One of the plants that ceased operation was represented by the ICWUC, who thereafter 
ceased participation in the study due to its diminished level of direct engagement and 
interest. A representative of the International Union of Operating Engineers (IUOE) 
subsequently joined the study oversight group. Ultimately, three U.S. plants (with an 
estimated eligible workforce of 300) participated between 2006 and 2012, and one of these 
plants ceased production of TDI in 2010 but continued the medical surveillance through 
2012 according to protocol.
Eligible workers, designated by a study coordinator at each site, were those who performed 
tasks in areas of potential TDI exposure (averaging over 10 hours per week throughout the 
year) or who performed tasks with a high potential for direct contact with TDI (averaging at 
least 24 times per year). More than one task with potential TDI exposure could be counted 
during a single shift. Eligible employees included those who had previously worked with 
other diisocyanates, or had concurrent exposures to other diisocyanates. Eligible workers 
had to be enrolled in the plants’ existing medical surveillance program. Contract workers 
were not eligible, as they were not enrolled in the plants’ existing, on-site medical 
surveillance programs. Recruitment of eligible workers by occupational health and safety 
staff occurred during health and safety meetings, medical surveillance program visits, and at 
the time of any reported exposure or health concern potentially related to TDI. No incentives 
to participate were offered.
Eligible workers completed a Participant Election Form that included the worker’s 
acknowledgement of informed consent. Workers who agreed to participate completed their 
first Periodic Questionnaire (including asthma symptoms). Participants then completed a 
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more detailed Intake Questionnaire and baseline spirometry within six months and 
subsequent Periodic Questionnaires and spirometry each year thereafter (Figure 1). Those 
electing not to participate were asked to record whether they had any respiratory symptoms 
and if they were working with TDI.
At any time, participants could withdraw from the study and were asked to complete both a 
form to indicate the reason for their withdrawal and a final Periodic Questionnaire (Figure 
1). Study participants who were transferred out of a job category with potential exposure to 
TDI to a new unit at the plant were asked to continue in the study. Approval for the study 
was obtained from both the NIOSH and Dow Chemical Company Institutional Review 
Boards.
Spirometry
NIOSH personnel visited each participating plant and provided spirometry training to plant 
occupational health personnel and furnished each plant with a spirometer (SensorMedics 
dry-rolling seal volume spirometer) and computer software (The Occupational Marketing 
Inc. (Houston, TX) (OMI) spirometry software) to assure consistency across plants. 
Spirometry results were sent to NIOSH for quality review before submission to the study 
database. NIOSH provided regular reports to the plant spirometry technicians regarding test 
quality.
Referral for Medical Evaluation of Possible Asthma
According to the protocol, participants who reported specific symptoms on the Periodic 
Questionnaire occurring at least four times within the past 12 months at the time of the 
questionnaire (wheezing; chest tightness or shortness of breath with wheezing; being 
awakened by cough, wheeze, or chest tightness; tightness in chest for longer than a minute; 
or a combination of chills, fever, cough, and muscle aches) or who demonstrated a specified 
loss of forced expiratory volume in one second (FEV1) (350 ml or 10% decline over one 
year or less) were to complete a more detailed Second Tier Questionnaire (See Appendix). 
Additionally, participants who presented with new respiratory symptoms or following a TDI 
exposure event were also asked to complete the Second Tier Questionnaire. If indicated, 
based on Second Tier responses, (i.e., TDI was one of the exposure agents, respiratory 
symptoms were present, and TDI-induced asthma could not be excluded) a worker was to be 
referred for clinical testing with serial peak flow and FEV1 while at work on normal duties 
with potential exposure to TDI, while restricted from TDI, and post-shift spirometry with 
pre- and post-bronchodilator measurements. A methacholine challenge could be added to the 
clinical evaluation if previous tests were not conclusive. Upon completion of this evaluation, 
all pertinent records were to be reviewed by a university-based, consulting pulmonologist.
The consulting pulmonologist made a determination for each case to be consistent with 
asthma, other respiratory disease, or normal respiratory status. If consistent with asthma, 
then a category was specified:
• consistent with non-work-related asthma;
• consistent with work-related asthma
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○ consistent with TDI-induced asthma,
○ consistent with Irritant-induced asthma/Reactive Airways Dysfunction 
Syndrome (RADS),
○ consistent with asthma induced by other agent(s),
○ indeterminate regarding agent; or
• indeterminate regarding work-relatedness
These classifications reflect a determination based on the study protocol, not clinical 
diagnoses. Medicolegal liabilities of each participating party were carefully considered 
during planning. Consequently, a core design concept was to avoid shifting responsibilities 
between the companies, NIOSH, and the ACC. Each company had its own, separate 
responsibility to its workers to prevent occupational disease and disability in its own 
workforce. The protocol was developed with an intent to avoid shifting any of the 
responsibilities for early detection, diagnosis, and removal from future exposure. The 
opinions of the occupational pulmonary disease expert supporting the study were shared 
with the respective plant medical departments. None-the-less, ultimate responsibility for 
diagnosis and clinical management remained with the employer’s medical staff serving each 
participating worker. At the conclusion of the study in 2012, follow-up with workers 
continued through the companies’ medical monitoring protocols.
Data Management
In the original data collection procedures, plants faxed study forms to a vendor external to 
NIOSH and the participating companies for manual data entry into a database. The vendor 
created a unique de-identified ID for each participant. The vendor shared periodic reports of 
surveillance activities with the medical surveillance task group (the plants’ medical directors 
and NIOSH staff). The group identified several limitations with this process: (1) plants did 
not consistently fax forms to the vendor in a timely manner; (2) feedback to the data sources 
was delayed by weeks and was not consistent; (3) participants who should complete a 
Second Tier Questionnaire were not identified at the time they reported symptoms or other 
triggering events resulting in untimely evaluation; and (4) the plants were not receiving 
regular and timely reports of participants who were due for monitoring.
In 2010, a quality control evaluation was conducted. The study team hired a project manager 
and implemented a real time, HIPAA compliant, Internet-based data collection tool created 
using the Research Electronic Data Capture (REDCap) system to improve the efficiency, 
quality, and functionality of the original data collection and management protocol.21 
REDCap provided a stream-lined process for rapidly building a database, an intuitive 
interface for collecting data with data validation, automated export procedures for data 
downloads, and other advanced features. The potential advantages to updating the system 
included timely access to data and improved feedback to plant medical personnel regarding 
next steps required to comply with the study protocol. Participants completed forms using a 
computer or paper form and the plant nurse entered results directly into REDCap and 
reviewing medical staff submitted the survey. Real time reports were generated to alert the 
plant personnel if follow-up was indicated and when participants were due for monitoring. 
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The project manager ran standard automated queries to identify instances where follow-up 
was indicated and worked with plant personnel to ensure the protocol was followed.
Worker Evaluation Survey
To further evaluate the program, a 10-item Worker Evaluation Questionnaire was mailed to 
164 participants in early 2011. The survey items used a Likert scale to rate the barriers and 
facilitators of study participation and also included a section for open ended comments.
RESULTS
Program Implementation
The three plants registered 269 eligible workers. As shown in Figure 2, 14 (5.2%) did not 
sign the Election Form required to enroll. Of the 255 who completed an Election Form, 193 
initially agreed to participate. Of the 62 who initially declined, eight later consented to 
participate, yielding a total of 201 participants (74.7%). Of the 201 who elected to 
participate, 79.6% completed the Intake or a Periodic Questionnaire and spirometry within 
six months. The initial participation rate, defined as the percentage of workers eligible who 
completed a questionnaire and spirometry within six months of registration was 59.5% 
(160/269). An additional 37 workers completed these after six months and were included in 
the analysis, resulting in 197 participants.
Table 1 summarizes the level of participation of the cohort, 121 (47.5%) participated until 
the end of the study, 67 (26.3%) volunteered and then withdrew, eight initially declined and 
then enrolled and one person volunteered, withdrew and then volunteered again. Of the 67 
who withdrew for reasons not specified, 46.5% were terminated, 28.2% were transferred out 
of the unit, and 19.7% decided not to participate (data not shown). Almost 50% of the 201 
who elected to participate completed at least five Periodic Questionnaires.
The demographic characteristics did not vary between the TDI workers who agreed to 
participate (n = 201) and did not participate (n = 54) (P > 0.05) (Table 2). In both groups, the 
majority of workers were male (93.5% participants, 87.0% non-participants) and White 
(67.7% participants, 64.8% non-participants). The majority of participants and non-
participants were between 36 and 50 years of age (54.2% and 59.3%, respectively). The 
mean and standard deviation years of employment at the time of enrollment was 11.8 ± 10.1 
for participants and 13 ± 9.9 for non-participants (Table 2). Four non-participants (7.4%) and 
32 participants (15.9%) had been employed for less than one year. Ten non-participants 
(18.5%) were employed for less than two years and 49 participants (24.3%) were employed 
for less than two years (data not shown).
Prior to 2010, 23 participants were eligible for a Second Tier Questionnaire; however, only 
four completed it the same day as called for in the protocol. The average time until 
completing the Second Tier was 14.3 months. After implementing REDCap, two 
participants eligible for a Second Tier Questionnaire completed it on the same day (and did 
not meet criteria for further evaluation).
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During the course of the study, 42 participants were eligible for a Second Tier 
Questionnaire. Records of the 23 participants identified by questionnaire without timely 
completion of the Second Tier Questionnaire and the eight participants identified by decline 
in FEV1 during the 2010 quality review of data, were reviewed by the consulting 
pulmonologist. During data analysis, 11 additional participants were identified as having a 
FEV1 decline; however their records were not sent to the consulting pulmonologist because 
data collection had ended. There was no automated method to identify FEV1 decline in real 
time during the study. Of the 42 participants who met criteria for further evaluation, no 
participants completed serial peak flow, one completed spirometry with bronchodilator 
testing, and another individual completed methacholine testing.
Potential Health Outcomes
Of the 31 workers whose records were sent to the consulting pulmonologist, nine (29%) 
were determined to have an evaluation consistent with asthma, one was consistent with other 
non-specified respiratory disease, and 21 were considered to have normal respiratory status 
as shown in Table 3. These classifications reflect a determination based on the study 
protocol, not clinical diagnoses. Of the nine with results consistent with asthma, seven 
(23%) were consistent with TDI-induced asthma, and two were indeterminate regarding 
work-relatedness. The one who was consistent with other respiratory disease was 
unspecified. Review of the study records indicated that four participants identified as having 
a condition consistent with TDI-induced asthma had been transferred from the TDI 
environment to a different location, two with specific TDI restrictions and two for non-
specified reasons. There was no documentation of transfer or restrictions for the other three 
and they continued in the monitoring program of the study.
Of the 54 who never participated, none had reported symptoms at the time they declined and 
38 (84.4%) were working with TDI. Of the 67 who withdrew from the study after enrolling, 
only one reported symptoms at the time of withdrawal and that person was one of the 
participants restricted from working with TDI.
Effectiveness of Methods to Identify Referrals for Medical Evaluation
Participants met criteria for further evaluation through five triggering events in the protocol. 
Table 4 shows the criteria met for further evaluation and the results from the consulting 
pulmonologist for the 31 eligible participants identified as of the study end date. Some 
participants were identified through more than one mechanism. Of the 31, 10 were identified 
through report of an acute inhalation event (3 of which were TDI exposures), four through a 
clinical encounter, seven through the Intake Questionnaire, nine through the Periodic 
Questionnaire and eight through decline in lung function (Table 4).
Five of the participants with findings consistent with TDI-induced asthma met criteria for 
further evaluation based on events outside of scheduled monitoring. Three reported an acute 
inhalation event and two others sought care for respiratory symptoms. Of the three with 
inhalation events, one was with TDI and two were with phosgene. Only two had an 
indication for further evaluation identified only on a scheduled questionnaire (data not 
shown).
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In this study, spirometry methods and equipment were standardized, and quality assurance 
was ongoing. The longitudinal design allowed multiple spirograms for each individual 
during the five year study. The loss of FEV1 in any given year did not lead to the timely 
evaluation of individual workers for possible asthma as called for in the study protocol due 
to lack of a mechanism to flag these changes. While it is possible that follow-up did occur 
without documentation as part of the study, this information is not available to the study 
investigators. Therefore, the utility of the spirometry performed for early identification of 
occupational asthma cannot be evaluated.
Experience of Participants
The Worker Evaluation Survey was mailed to 164 participants and 82 (50%) completed it. 
Those responding selected responses indicating that it was easy to arrange their schedule for 
medical screenings (93%) and to complete the Periodic Questionnaire (91%). The majority 
selected the response that they “felt better knowing that the management of their plant was 
concerned about their health” (90%). Most also reported that the doctor or health 
professional staffing their plant’s medical unit listened carefully to what they have to say 
(99%) and answered all of their questions (96%). Eighty-seven percent mildly or strongly 
agreed that the study spirometry equipment was no different than the routine spirometry 
equipment used by the plant. Twenty-three percent thought that “participating in the study 
was too much trouble for what they got out of it” and 18% reported worrying that if they 
were sent for additional medical testing it would affect their employment status. Overall, 
91% reported they got their breathing test results back within 30 days of the test. Overall, 
76% reported that they received the results of their exposure monitoring for the study.
DISCUSSION
This paper reports on a longitudinal medical monitoring program offered to all potentially 
exposed non-contract TDI production workers in the U.S. Representatives from the ACC, 
NIOSH, engaged labor unions, and all the primary producers of TDI in the U.S. worked 
together to design a prospective study to investigate the association between TDI exposure 
and OA. A detailed protocol including TDI exposure assessment, medical monitoring, 
criteria for identifying workers requiring further medical evaluation, and a structured clinical 
evaluation was developed. The results presented here focus on implementation of the 
medical monitoring protocol and initial findings.
A short, self-administered questionnaire and screening spirometry of TDI workers triggered 
criteria for further testing in 21% over a 5 year period when administered twice annually. 
Plant medical staff found it challenging to reliably apply the complicated, multistage 
medical protocol which delayed the further evaluations called for. What, if any, clinical 
impact resulted is unknown. This experience indicates that if data collected as a part of 
routine, on-going medical surveillance of potentially exposed workers are to be relied on to 
assess the safety and healthfulness of a workplace in scientific literature, rigorous methods 
to assure timely and complete follow-up to document each worker’s occupational health are 
essential. Even experienced, highly committed occupational health practitioners produce 
data of limited scientific value for measuring asthma incidence and effectiveness of medical 
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surveillance programs without detailed, timely program management throughout data 
collection.
The study team faced specific challenges while implementing the standardized protocol 
across multiple production plants. The study team hypothesized feasibly achieving a 75% 
participation rate because most eligible employees were already included in their plant’s 
medical surveillance program. However, recruiting and retaining such a high participation 
rate proved challenging, and the initial participation rate was 59.5%. Because three plants 
ceased TDI production before the study began, the eligible study size was reduced to a total 
of 269 workers from the three remaining U.S. plants eligible to participate. Of that reduced 
number, 54 never enrolled during the study period. Non-participants were not prompted for 
their reasons to opt out of the study, but they had similar demographic characteristics and 
durations of employment as participants and none reported symptoms at the time they 
declined. Most of the enrolled workers (n = 67) who discontinued participation did so 
because they were either transferred out of the unit (28.2%) or terminated employment 
(46.5%). Overall 121 workers remained in the study throughout its duration and completed 
periodic screening sessions with some workers completing up to eight sessions.
Overall, the study identified 42 workers who were eligible for evaluation with the more 
detailed questionnaire due to an acute inhalation event, reporting to the clinic with 
symptoms, responses to symptom questions, or a decline in lung function. However, 
methods to ensure timely implementation of the protocol for participants identified for 
further evaluation proved to be essential. Only six participants out of 44 completed the 
Second Tier Questionnaire according to protocol. Review of Figures 1 and 2 provide a 
picture of the complexity of the protocol which the study team designed and then attempted 
to implement. The need for a study coordinator to monitor implementation of the protocol 
was not recognized until several years into data collection.
Implementation of the web-based data collection system enhanced application of the study 
protocol process, however, this system was not implemented until the last 18 months of the 
study. It seems reasonable to hypothesize that data acquisition with such a data collection 
system from study onset could have improved this study and should be considered in the 
design of future studies of on-going, medical monitoring programs of production workers.
Because there was a significant delay in completing most Second Tier evaluations, the 
investigators conservatively sent records of all potential cases identified prior to the protocol 
revision to the consulting pulmonologist for review (n = 31). A total of 19 workers were 
identified with FEV1 decline that met criteria for further evaluation, 11 after the study 
ended.
Despite the lack of implementation of the medical protocol specified in the study to quickly 
identify asthma developing in this population, 29% of the possible cases reviewed by the 
pulmonologist were thought to have developed asthma and 23% were thought to have 
developed isocyanate-induced asthma. This suggests that the criteria for further evaluation 
had utility. While this study does not provide enough detailed data to evaluate the efficacy of 
each component of the monitoring system, it does suggest that access to healthcare providers 
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well versed in recognizing occupational asthma is critical for workers potentially exposed to 
isocyanates, as more than half of the cases presented for evaluation outside of the scheduled 
monitoring activities.
Monitoring programs that include spirometry should include a mechanism to immediately 
compare each test to prior tests in order to assess potential declines over time.22 Research 
studies should include a time after the termination of periodic monitoring to follow-up on 
participants who trigger an evaluation towards the end of the program.
Maintaining uniformity of procedures and ensuring high quality data collection and 
management is essential for data aggregation across plants and subsequent data analyses 
regarding the diagnosis and prevention of TDI-induced asthma. Design of the original data 
collection, entry, and management procedures focused on assuring confidentiality of the 
participating workers and their respective plants. One result was that the protocol lacked 
provisions for immediate, i.e. before the participant left the plant medical unit, feedback to 
the plant nurses and physicians. Many challenges occurred while collecting and aggregating 
paper forms via fax from the plants. This meant that notifying plant staff of missing 
questionnaires, spirograms, or failed escalation of the multistep, medical evaluation process 
was inefficient.
Upon evaluation of the data collection and management procedures in 2010, the study team 
hired a project manager and implemented the REDCap data collection system to improve the 
efficiency, quality, and functionality of the original data collection and management 
protocol. Advantages of entering data into REDCap included relieving the burden of faxing 
the forms to the vendors and likely reduced the potential for error resulting from performing 
manual data entry. The REDCap system included automated quality control checks with skip 
logic and context sensitivity to streamline data collection. After implementing the REDCap 
system, the staff in the plant medical units gained more control of the process and were 
better able to schedule and recall the study participants as called for by the study protocol. 
This system allowed for timely feedback to the plants, immediate identification of 
participants who should be entered into the staged medical protocol, and regular and timely 
reports of participants who were due for screening.
The experience of the study team has implications for both medical monitoring for 
respiratory disease as well as scientific analysis of the data produced from that monitoring 
among workers exposed to agents known to cause asthma. Rapid recognition of early signs 
of possible asthma requires timely clinical follow-up of reported symptoms, reported 
exposure events, and changes in spirometry measurements. REDCap is a research tool not 
routinely available in the occupational health practice setting. However, emerging 
technologies provide opportunities to implement clinical decision support mechanisms 
which could assist with prompt recognition of “triggers” for further evaluation. Systems 
exist to provide immediate visual displays of excessive longitudinal lung function decline for 
individual workers as well as groups of workers (https://www.cdc.gov/niosh/topics/
spirometry/spirola.html).
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The Worker Evaluation Survey suggests that overall the participants viewed the program 
positively. The majority who responded felt that the management cared about their health, 
the health professional listened to their concerns and that participation was not troublesome. 
There was some stated concern that if they were sent for additional testing it would affect 
their employment. The survey revealed that workers were not receiving their exposure 
monitoring results which led to adjustments in communications to remedy this problem.
CONCLUSION
Medical monitoring programs were implemented by all the U.S.-based producers of TDI at 
the plant locations prior to this study. This study built upon this base of long-standing 
isocyanate medical surveillance programs to standardize a medical monitoring program 
across plants for a prospective epidemiological study. Although the majority of the 
participants meeting the criteria for further evaluation were identified through 
questionnaires, additional methods in the surveillance program such as spirometry and 
respiratory exposure events identified additional potential cases.
Repeated breakdowns in follow-up steps called for by the study protocol indicate that timely 
means to assure evaluation and feedback to personnel involved in data collection is essential 
to the success of medical monitoring programs among workers. Systems, either automated 
or manual, are needed to help ensure complete and consistent application of the detailed 
study protocol requirements to pre-existing, plant-specific medical surveillance programs. 
Additionally, when conducting research in such settings, a study coordinator is most likely 
needed to fully utilize these protocol compliance monitoring systems. Without a real-time 
mechanism to ensure full compliance with the study protocol, conclusions drawn from data 
generated in the course of on-going medical monitoring programs should be viewed with 
caution. While data collected in this study does not provide conclusive evidence as to the 
utility of any one component of the medical surveillance program, the study demonstrates 
the importance of immediate feedback to occupational health personnel conducting such 
monitoring to ensure appropriate follow-up.
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Appendix: Criteria for Second Tier Questionnaire
Items on the Periodic Questionnaire that triggered administration of a Second Tier 
Questionnaire included having answered positively to experiencing any of the following 
symptoms at least four times within the past 12 months: (1) Had wheezing or whistling in 
the chest, apart from when you have a cold?; (2) Had an attack of chest tightness or 
shortness of breath with wheezing or whistling in the chest?; (3) Been awakened by 
coughing wheezing or chest tightness?; (4) Felt tightness in your chest for longer than a 
minute?; and (5) Had an illness with chills, fever, cough and muscle aches?
If a worker answered positively for questions items 1–5 above on the Intake Questionnaire, 
he or she was eligible for a Second Tier Questionnaire. In addition, participants enrolled in 
the study could visit the clinic to report symptoms consistent with asthma from a TDI 
exposure. These symptoms were recorded on the clinical encounter form, and the protocol 
dictated that further evaluation of eligibility for the staged medical protocol to assess asthma 
would be implemented. Non-routine exposure episodes were identified through a 
compilation of Acute Inhalation Worksheets, indicating the occurrence of such exposure 
incidents and the severity of symptoms associated with those incidents. These workers were 
also referred for medical evaluation to assess eligibility for the staged medical protocol.
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Figure 1. 
Schematic of cohort enrollment into the study and participation in the medical monitoring 
program for TDI workers including questionnaires, spirometry, and implementation of 
medical evaluation.
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Figure 2. 
Eligible TDI workers who volunteered to participate, both initially and after data collection 
began, and who did not volunteer to participate or did not provide data
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Table 1
Participation Status of Cohort of TDI Workers in a Medical Surveillance Program (n = 255)
Participation Status N (%)
Never 54 (21.2)
Participated until study end 121 (47.5)
Volunteered then withdrew 67 (26.3)
Initially declined then enrolled 8 (3.1)
Volunteered, withdrew, volunteered 1 (0.4)
Volunteered, questionnaire, no spirometry 4 (1.6)
TDI, toluene diisocyanate
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Table 2
Demographic Characteristics of TDI Workers who Agreed to Participate (n = 201) and Did Not Participate (n 
= 54)*
Characteristic Participants (n = 201) Non-Participants (n = 54)
Gender (%)
 Male 188 (93.5) 47 (87.0)
 Female 13 (6.5) 7 (13.0)
Race (%)
 African American 34 (16.9) 8 (14.8)
 Caucasian 136 (67.7) 35 (64.8)
 Hispanic 29 (14.4) 10 (18.5)
 Other 2 (1.0) 1 (1.9)
Age group (%)
 21–35 Years 51 (25.4) 12 (22.2)
 36–50 Years 109 (54.2) 32 (59.3)
 51–65 Years 41 (20.4) 10 (18.5)
 Mean years employed (SD) 11.8 (10.1) 13 (9.9)
*P > 0.05 for all comparisons between the Participants and Non-Participants
SD, standard deviation; TDI, toluene diisocyanate
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Table 3
Determination by the Consulting Pulmonologist for 31 TDI Workers
Determination N (%)
Consistent with Asthma 9 (29%)
 Consistent with Non-Work-Related 0 (0%)
 Consistent with TDI-induced 7 (78%)
 Indeterminate Regarding Work-Relatedness 2 (22%)
Consistent with Other Respiratory Disease 1 (3%)
Normal Respiratory Status 21 (68%)
TDI, toluene diisocyanate
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Table 4
Events Prompting Completion of a More Detailed Respiratory Questionnaire for 31 TDI Workers, Overall and 
by Determination by the Pulmonologista
Overall (n = 31) Determination by Pulmonologist
Consistent with 
Asthma (n = 9)
Other Respiratory 
Disease (n = 1)
Normal Respiratory 
Status (n = 21)
Event N N N N
Acute Inhalation Event 6 (19.4%) 1 (11.1%) 0 (0.0%) 5 (23.8%)
Clinical Encounter 2 (6.5%) 2 (22.2%) 0 (0.0%) 0 (0.0%)
Acute Inhalation and Clinical Encounter 1 (3.2%) 1 (11.1%) 0 (0.0%) 0 (0.0%)
Intake Questionnaire 4 (12.9) 2 (22.2%) 1 (100%) 1 (4.8%)
Intake Questionnaire and Acute Inhalation 1 (3.2%) 0 (0.0%) 0 (0.0%) 1 (4.8%)
Periodic Questionnaire 5 (16.1%) 1 (11.1%) 0 (0.0%) 4 (19.0%)
Periodic Questionnaire and Acute 
Inhalation 1 (3.2%) 1 (11.1%) 0 (0.0%) 0 (0.0%)
Periodic Questionnaire, Acute Inhalation, 
and Clinical Encounter 1 (3.2%) 0 (0.0%) 0 (0.0%) 1 (4.8%)
Periodic Questionnaire and Intake 
Questionnaire 2 (6.5%) 0 (0.0%) 0 (0.0%) 2 (9.5%)
Decline in FEV1 8 (25.8%) 1 (11.1%) 0 (0.0%) 7 (33.3%)
a13 workers had results that were not sent to the pulmonologist, 11 met the criteria for further evaluation by the pulmonologist but were identified 
after the study ended, and two were prompted to complete a more detailed questionnaire but did not meet criteria for further evaluation by the 
pulmonologist.
FEV1, forced expiratory volume in one second; TDI, toluene diisocyanate
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